Gaelic Laboratories, an Ireland-based manufacturer of beta-lactam (penicillin) products established in 2022, has acquired Athlone Laboratories, a long-standing developer and manufacturer of oral-dose beta-lactam medicines. The acquisition strengthens Gaelic Laboratories’ market position, expands manufacturing capabilities, and unlocks supply-chain efficiencies.

Ireland’s supportive regulatory framework, business-friendly environment, and political stability have positioned the country as a global hub for pharmaceutical manufacturing. Bringing together Ireland’s two beta-lactam manufacturers creates a stronger, more integrated platform with opportunities for scale, operational efficiency, and long-term growth, delivering value for customers, partners, and stakeholders.

Both companies have established reputations in the manufacture of beta-lactam antibiotics. Their complementary product portfolios and capabilities are expected to enhance market reach, broaden offerings, and improve operational efficiency. The acquisition aligns with Gaelic Laboratories’ long-term strategy to build leadership in the manufacturing and supply of generic beta-lactam medicines.

Commenting on the transaction, Brian Morrissey, General Manager of Gaelic Laboratories, said the deal is expected to generate significant financial and operational benefits, including manufacturing consolidation, revenue growth, and regulatory efficiencies. He added that Athlone Laboratories plays a critical role in the beta-lactam supply chain and offers strong operational synergies with Gaelic’s existing manufacturing platform.

Gaelic Laboratories confirmed that all employees at the Athlone site, including the current management team, will be retained to ensure business continuity. Athlone Laboratories’ executive leadership will report to Brian Morrissey, who will assume oversight of both organisations.

The combined workforce has now grown to approximately 120 employees. Gaelic Laboratories said it is implementing structured integration programmes to ensure a smooth transition while preserving Athlone’s expertise and operational strengths.

All existing product lines and customer contracts will continue without interruption. Customers are expected to benefit from enhanced manufacturing efficiency, continued investment in facilities, expanded product portfolios, and aligned quality, compliance, and IT systems.

The acquisition brings together Ireland’s only two beta-lactam manufacturers, creating a consolidated manufacturing platform with global reach. Together, the companies serve customers across Europe, the UK, the Middle East, North Africa, Asia-Pacific, Canada, Iraq, and Brazil, reinforcing Ireland’s role in global pharmaceutical manufacturing.